Jun. 21, 2017

Novopyxis – The first start-up identified by LEO Science & Tech Hub

LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.

The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.

Read the press release

News from the hub

Oct. 2018 24 LEO Science & Tech Hub Partners with Wearifi and Northwestern University to Develop Wearable Device for Dermatology Research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, announced today that they will partner with Wearifi Inc. and the Center for Bio-Integrated Electronics at Northwestern University to investigate the clinical potential of next-generation wearable electronics in dermatology research. Wearifi designs and develops the world’s smallest, battery-free wearable device. The collaboration […]

Read more
Sep. 2018 18 LEO Science & Tech Hub Partners with Epicore Biosystems to Explore Wearable Skin Sensors to Improve Dermatologic Treatment Regimens

LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, has announced a new partnership with Epicore Biosystems focused on exploring the use of a non-invasive, wearable sweat sensor to measure prognostic biomarkers in real time, monitor patient response and inform treatment decisions. The initial project will include a proof of concept study in […]

Read more